



Systemic Transdermal
Local Transdermal
Dermatological
Skincare
Cosmetics
Oral Health
Haircare
Surface Hygiene
Fabric care

ABN 72 056 482 636

284 Oxford Street,
Leederville 6007,
Western Australia
Telephone +61 8 9443 3011
Facsimile +61 8 9443 9960
www.obj.com.au

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations transdermally.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhanced diffusion and to alter the permeability of certain biological and non-biological targets in the skin.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

US Patent Office Allows Dermaportation Patent

OBJ (ASX: OBJ) advises that it has received notification from its patent attorney that the patent application, protecting the Company's powered electromagnetic fields drug delivery technology for the USA, has proceeded to allowance.

The Notice of Allowance for United States Patent Application 10/595,964 accepted all claims. The Company has been notified that subject to the payment of applicable fees, that the United States Patent Office would move to grant the full patent within 3 months.

Dermaportation was the Company's first drug delivery technology, later expanded to include the eM-patch magnetic micro-array technology and the Field-in-Motion (FIM) energy redirection technology.

Dermaportation is currently being developed for a number of applications and the allowance of a US patent over this key drug delivery technology is expected to assist with partnering discussions.

- Ends -